See all locations for this study
Phase 2Recruiting

TRUDI: TDXD+Durva in HER2+/Low IBC

Sponsored by Filipa Lynce, MD

About this study

The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab

Enrolling at this location

Dana Farber Cancer Institute

Boston, Massachusetts

I'm interested

This study also enrolls at 2 other locations. See all.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.